Arkema rises after Q3 earnings beat, FY guidance confirmation

By Reuters News

** Shares in Arkema AKE.PA are up 3.4%, on better-than-expected Q3 revenue, and 2026 outlook confirmation

** The French specialty chemicals maker reports sales for Q3 at €2.36 billion ($2.66 billion), ahead of the €2.27 bln consensus compiled by the company

** J.P.Morgan also notes a slight beat in Q3 adjusted EBITDA at €332 mln (+1% vs consensus), flagging results slightly better than the brokerage had forecast across all the key divisions in Specialty Materials

** The company maintains its 2026 outlook of a slightly higher year-on-year EBITDA at constant FX

** The broker says the guidance confirmation signals Arkema's ability to deliver a Q4 result better than normal seasonal patterns would imply, which "should be supportive for the shares"

** Including today's gains, the stock is up 14.7% year-to-date


($1 = 0.8880 euros)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk